67Cu-SAR-BBN for Prostate Cancer

Bamf Health, Inc, Grand Rapids, MI
Prostate Cancer+1 More Conditions67Cu-SAR-BBN - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial hopes to find out if a new treatment is safe and effective in treating prostate cancer that can't be treated with another method.

Eligible Conditions
  • Castration-resistant Prostate Cancer
  • Prostate Cancer

Treatment Effectiveness

Study Objectives

12 Primary · 0 Secondary · Reporting Duration: Up to 5 years

Up to 12 months
Incidence of 64Cu-SAR-BBN treatment-emergent adverse events [Safety and tolerability]
Incidence of 67Cu-SAR-BBN treatment-emergent adverse events [Safety and tolerability]
Up to 14 weeks
Incidence of dose limiting toxicities [Safety and tolerability] of 67Cu-SAR-BBN
Recommended dose of two doses of 67Cu-SAR-BBN
Safety and tolerability of 67Cu-SAR-BBN
Up to 24 weeks
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in electrocardiogram (ECG) parameters
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in vital signs
Up to 5 years
Efficacy of 67Cu-SAR-BBN in terms of Prostate Specific Antigen (PSA) response
Efficacy of 67Cu-SAR-BBN in terms of radiographic response
Incidence of 67Cu-SAR-BBN adverse event of special interest [Safety and tolerability]
Up to 52 weeks
Safety and tolerability of 67Cu-SAR-BBN: Number of Participants with changes from baseline in laboratory results
Up to 8 weeks
Maximum tolerated dose (MTD) or maximum feasible dose (MFD) of a single dose of 67Cu-SAR-BBN

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

67Cu-SAR-BBN
1 of 1

Experimental Treatment

38 Total Participants · 1 Treatment Group

Primary Treatment: 67Cu-SAR-BBN · No Placebo Group · Phase 1 & 2

67Cu-SAR-BBNExperimental Group · 2 Interventions: 67Cu-SAR-BBN, 64Cu-SAR-BBN · Intervention Types: Drug, Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Clarity Pharmaceuticals LtdLead Sponsor
9 Previous Clinical Trials
317 Total Patients Enrolled
1 Trials studying Prostate Cancer
30 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 6 more months.

Frequently Asked Questions

Are there any available vacancies for this research project?

"As of the most recent update on April 11th, 2023; this clinical trial is not presently accepting any patients. Despite that, there are 1249 other trials actively recruiting across a variety of conditions and treatments." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.